Firefly Neuroscience, Inc. (NASDAQ:AIFF) Short Interest Update

Firefly Neuroscience, Inc. (NASDAQ:AIFF) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 1,551,962 shares, a growth of 300.2% from the February 26th total of 387,780 shares. Based on an average daily volume of 45,958,225 shares, the short-interest ratio is presently 0.0 days. Currently, 11.7% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Firefly Neuroscience Stock Up 79.8%

Shares of AIFF opened at $3.02 on Friday. The business’s fifty day moving average is $1.21 and its 200 day moving average is $1.68. Firefly Neuroscience has a 12-month low of $0.62 and a 12-month high of $4.51. The stock has a market cap of $42.94 million, a P/E ratio of -1.44 and a beta of 1.92.

Institutional Investors Weigh In On Firefly Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Firefly Neuroscience by 393.3% in the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after acquiring an additional 401,085 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after purchasing an additional 58,067 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Firefly Neuroscience in the fourth quarter worth approximately $53,000. Finally, Savvy Advisors Inc. bought a new position in shares of Firefly Neuroscience in the third quarter valued at approximately $63,000. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.